Advertisement
Advertisement
Megapime Hospi

Megapime Hospi

cefepime

Manufacturer:

NCPC Hebei Huamin Pharma

Distributor:

Alkem Lab
Concise Prescribing Info
Contents
Cefepime HCl
Indications/Uses
Moderate to severe pneumonia caused by Strep pneumoniae, including cases associated w/ concurrent bacteremia, P. aeruginosa, Klebsiella pneumoniae, or Enterobacter spp. Empiric therapy for febrile neutropenic patients. Uncomplicated & complicated UTI including pyelonephritis, uncomplicated skin & skin structure infections, complicated intra-abdominal infections (used in combination w/ metronidazole).
Dosage/Direction for Use
Adult Moderate to severe pneumonia due to S. pneumoniae, P. aeruginosa, K. pneumoniae, or Enterobacter spp 1-2 g IV every 12 hr for 10 days. Empiric therapy for febrile neutropenic patients 2 g IV every 8 hr for 7 days or until resolution of neutropenia. Mild to moderate uncomplicated or complicated UTI including pyelonephritis due to E. coli, K. pneumoniae, or P. mirabilis including cases associated w/ concurrent bacteremia 0.5-1 g IV or IM every 12 hr for 7-10 days. Severe uncomplicated or complicated UTI including pyelonephritis due to E. coli or K. pneumoniae including cases associated w/ concurrent bacteremia 2 g IV every 12 hr for 10 days. Moderate to severe uncomplicated skin & skin structure infections due to S. aureus or S. pyogenes 2 g IV every 12 hr for 10 days. Complicated intra-abdominal infections (used in combination w/ metronidazole) caused by E. coli, viridans group strep, P. aeruginosa, K. pneumoniae, Enterobacter spp or B. fragilis 2 g IV every 12 hr for 7-10 days. Renal impairment CrCl >60 mL/min 500 mg, 1 g or 2 g every 12 hr, 30-60 mL/min 500 mg, 1 g, or 2 g every 24 hr, 11-29 mL/min 500 mg, 1 g or 2 g every 24 hr, <11 mL/min 250 mg, 500 mg or 1 g every 24 hr. CAPD 500 mg, 1 g, or 2 g every 48 hr. Hemodialysis 1 g on day 1, then 500 mg every 24 hr thereafter or 1 g every 24 hr. Ped patient (2 mth-16 yr) up to 40 kg Uncomplicated & complicated UTI including pyelonephritis, uncomplicated skin & skin structure infections, & pneumonia 50 mg/kg/dose every 12 hr. 50 mg/kg/dose every 8 hr for febrile neutropenic patients.
Contraindications
Hypersensitivity to cefepime, cephalosporins, penicillins or β-lactam antibiotics.
Special Precautions
Cross-sensitivity among β-lactam antibiotics. Consider C. difficile-associated diarrhea in all patients who present diarrhea following antibiotic use; discontinue if suspected or confirmed. Prolonged use. Monitor prothrombin time in patients at risk & administer exogenous vit K. +ve direct Coombs' test. Individuals w/ a history of GI disease particularly colitis. Patients should be instructed to inform their healthcare provider at once of any neurological signs & symptoms, including encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, & coma), myoclonus, & seizures. Renal & hepatic impairment. Pregnancy & lactation.
Adverse Reactions
Local reactions including phlebitis, pain &/or inflammation, rash. Colitis including pseudomembranous colitis, diarrhea, fever, headache, nausea, oral moniliasis, pruritus, urticaria, vaginitis, vomiting. +ve Coomb's test (w/o hemolysis), decreased P, increased ALT/SGPT, AST/SGOT, eosinophils, abnormal PTT; increased alkaline phosphatase, BUN, Ca, creatinine, P, K, total bilirubin, decreased Ca, hematocrit, neutrophils, platelets, WBC.
Drug Interactions
Increased potential of nephrotoxicity & ototoxicity w/ high doses of aminoglycosides. Nephrotoxicity w/ potent diuretics eg, furosemide.
MIMS Class
Cephalosporins
ATC Classification
J01DE01 - cefepime ; Belongs to the class of fourth generation cephalosporins. Used in the systemic treatment of infections.
Presentation/Packing
Form
Megapime Hospi powd for inj 1 g
Packing/Price
1's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement